These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Hormonal contraception--side effects and surgical aspects (author's transl)]. Göretzlehner G; Carol W; Köhler G Zentralbl Chir; 1980; 105(24):1601-16. PubMed ID: 7015744 [TBL] [Abstract][Full Text] [Related]
43. Low levels of cryofibrinogenaemia and peripheral circulatory dysfunction. Kuipers JG; Kellett J; May D Ir Med J; 1991 Jun; 84(2):68-9. PubMed ID: 1894502 [TBL] [Abstract][Full Text] [Related]
44. [First experiences with ovosiston in new dosage--a comparative observation of oral contraception with "old" and "new" Ovosiston]. Zwahr C Dtsch Gesundheitsw; 1969 Nov; 24(46):2189-94. PubMed ID: 5385552 [No Abstract] [Full Text] [Related]
45. [Incremental program of contraceptive care of women]. Neumann HG; Rothe K Z Arztl Fortbild (Jena); 1983; 77(20):841-3. PubMed ID: 6659577 [No Abstract] [Full Text] [Related]
46. [From pill to pill: oral contraception, venous thrombosis and coagulation disorders]. Vandenbroucke JP Verh K Acad Geneeskd Belg; 2001; 63(3):243-52; discussion 252-5. PubMed ID: 11499345 [TBL] [Abstract][Full Text] [Related]
47. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Johnson JV; Lowell J; Badger GJ; Rosing J; Tchaikovski S; Cushman M Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of risk factors associated with vascular thrombosis in women on oral contraceptives. Possible role of anti-sex steroid hormone antibodies. Beaumont V; Lemort N; Beaumont JL Artery; 1983; 11(5):331-44. PubMed ID: 6661039 [TBL] [Abstract][Full Text] [Related]
49. Clinical hypercoagulability and oral contraceptives. von Kaulla E; von Kaulla KN; Droegemueller W Rocky Mt Med J; 1972 Jun; 69(6):33-6. PubMed ID: 5031944 [No Abstract] [Full Text] [Related]
50. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [TBL] [Abstract][Full Text] [Related]
52. Chronic intravascular coagulation. Clinical spectrum and diagnostic criteria, with special emphasis on metabolism, distribution and localization of I 131 -fibrinogen. Straub PW Acta Med Scand Suppl; 1971; 526():1-95. PubMed ID: 5292077 [No Abstract] [Full Text] [Related]
53. [Prevention of thromboembolic side effects of oral contraceptives: methodologic recommendations]. Póka R; Balogh I; Ajzner E; Nagy IG Orv Hetil; 1998 Apr; 139(14):815-8. PubMed ID: 9569728 [TBL] [Abstract][Full Text] [Related]
54. The effect of oral contraceptives on factor VIII levels. Crowell EB; Clatanoff DV; Kiekhofer W J Lab Clin Med; 1971 Apr; 77(4):551-7. PubMed ID: 5554340 [No Abstract] [Full Text] [Related]
55. The effects of oral estrogen-progestin compounds on blood coagulation factors. Hodges RM Int J Fertil; 1968; 13(4):349-53. PubMed ID: 5700392 [TBL] [Abstract][Full Text] [Related]
56. Cerebral ischaemic lesions and oral contraception. Kjaer M; De Fine Olivarius B; Waarst A Dan Med Bull; 1971 Dec; 18(6):129-37. PubMed ID: 5136191 [No Abstract] [Full Text] [Related]